Cargando…

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

The 2017 version of the European LeukemiaNet (ELN) recommendations, by integrating cytogenetics and mutational status of specific genes, divides patients with acute myeloid leukemia into 3 prognostically distinct risk categories: favorable (ELN2017-FR), intermediate (ELN2017-IR), and adverse (ELN201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, Venditti, Adriano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043923/ https://www.ncbi.nlm.nih.gov/pubmed/34731884 http://dx.doi.org/10.1182/bloodadvances.2021005717

Ejemplares similares

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey
por: Valentini, Caterina Giovanna, et al.
Publicado: (2021)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
por: Palandri, Francesca, et al.
Publicado: (2020)

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
por: Breccia, M., et al.
Publicado: (2022)

The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study
por: Efficace, Fabio, et al.
Publicado: (2021)

Fatigue of newly diagnosed patients with acute myeloid leukemia: comparison to the general population and investigation of predictive factors
por: Oswald, Laura B., et al.
Publicado: (2021)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study
por: Marasco, Vincenzo, et al.
Publicado: (2022)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
por: Chiaretti, Sabina, et al.
Publicado: (2021)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
por: Fazio, Francesca, et al.
Publicado: (2022)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019)

P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)
por: Silvestrini, Giorgia, et al.
Publicado: (2023)

Physicians’ Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform
por: Efficace, Fabio, et al.
Publicado: (2022)

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
por: Palmieri, Raffaele, et al.
Publicado: (2020)

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
por: Cefalo, Mariagiovanna, et al.
Publicado: (2019)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Therapy-related Myeloid Neoplasms: Considerations for Patients’ Clinical Evaluation
por: Palmieri, Raffaele, et al.
Publicado: (2023)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA
por: Efficace, Fabio, et al.
Publicado: (2023)

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
por: Efficace, Fabio, et al.
Publicado: (2021)

Experiences with a researcher-centric ELN
por: Badiola, Katrina A., et al.
Publicado: (2015)

The New ELN Recommendations for Treating CML
por: Hehlmann, Rüdiger
Publicado: (2020)

La conjuración de Venecia, año de 1310 /
por: Martínez de la Rosa, Francisco, 1787-1862
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_p06uctl2qtf7qh1vn0msis00vf